Clinical Trial Portfolio Monitoring

Context: A major tools and technologies manufacturer wished to implement a ‘hunter’ strategy, proactively targeting late stage academic and early stage industrial clients to integrate their proprietary products into manufacturing processes earlier than previously. However, the company’s business development team were faced with a barrage of potential technologies to pursue from trade and academic literature and conferences. For example, CAR-T, ADCs, gene therapies and CRISPR platforms.

Solution: Through discussion with the client, IPAV identified that the IP landscaping was an inappropriate intelligence solution if used in isolation as it may identify technologies that are in an early stage of commercial development, and not yet requiring GMP solutions that was the clients expertise. Therefore, IPAV using proprietary clinical trial landscaping tools, evaluated the stage and magnitude of clinical development of all candidate technologies

Outcome: The client identified that ADCs were of significant GMP manufacturing interest today; however, was not futuristic enough for the ‘hunter’ team and the need was best served by other internal sales teams. However, IPAV did identify the most appropriate emerging area for the company to target. We also respect CDAs with our clients, so won’t publish the outcome here. But the client seems happy!